Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
基本信息
- 批准号:10281141
- 负责人:
- 金额:$ 32.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-20 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:ActinsBiocompatible MaterialsBiologicalBiologyBiophysical ProcessBiophysicsCardiac MyocytesCell NucleusCell physiologyCellsCuesCytoskeletonDataDevelopmentDisease modelDistantDrug ScreeningEpigenetic ProcessExtracellular MatrixF-ActinFibroblastsFocal AdhesionsG ActinGene ExpressionGene TargetingGenesGenomicsHistone AcetylationMediatingMicrofilamentsModificationNeuronsNuclearNuclear TranslocationPhenotypePlayProcessRegenerative MedicineRegulationRoleSiteSomatic CellSurfaceTestingTissue EngineeringTransgenesWorkbasecell typecellular engineeringcofilindepolymerizationdesigndrug discoveryepigenomicsexperiencehistone acetyltransferaseinduced pluripotent stem celllive cell imagingmigrationmultidisciplinarynovelnovel strategiesnucleocytoplasmic transporttranscription factortranscriptomics
项目摘要
Project Summary
Cell reprogramming represents a major advancement in biology, and has wide applications in
regenerative medicine, disease modeling and drug screening. During cell reprogramming, cells experience
epigenetic changes that result in a cell phenotype switch. However, whether and how biophysical factors
regulate cell reprogramming through epigenetic modifications are not well understood. We have found that
biophysical factors, specifically extracellular matrix (ECM) stiffness, has profound effects on epigenetic
state and the conversion of fibroblasts into induced neuronal (iN) cells, with the highest efficiency at an
intermediate ECM stiffness, which is regulated by focal adhesions and the cytoskeleton. In addition, we
have discovered that actin assembly and transport into nucleus plays an important role in epigenetic
modulation. Based on our preliminary data, we hypothesize that (1) biophysical cues such as ECM
stiffness regulates FAs, actin assembly/disassembly, nuclear transport of actin, and thus, HAT activity to
modulate the epigenetic state and cell reprogramming process and (2) an intermediate level of stiffness is
optimal for epigenetic remodeling and cell reprogramming. To test our hypothesis, we propose three
Specific Aims: (1) Investigate how matrix stiffness regulates iN reprogramming through FAs and actin
cytoskeleton, (2) Elucidate how matrix stiffness modulates HAT and the epigenetic state to turn on neuronal
genes during iN reprogramming, and (3) Determine the role of actin nuclear transport in matrix stiffness-
modulation of HAT and epigenetic state during iN reprogramming. We have assembled a multidisciplinary
team with expertise on mechanobiology, cell engineering, high throughput genomic and epigenomic
analysis, and live cell imaging to work together and investigate the underlying biophysical and biological
mechanisms. Our proposed studies will be one of the first to elucidate how ECM stiffness regulates
transcriptomic and epigenetic changes for cell reprogramming, and how ECM stiffness modulates focal
adhesions and the cytoskeleton for cell reprogramming. Findings from this project will unravel new
mechanisms of cell fate determination, which will have wide applications in cell and tissue engineering,
disease modeling and drug discovery, and provide a rational basis for the optimization and development of
novel biomaterials for somatic cell reprogramming.
项目概要
细胞重编程代表了生物学的重大进步,在以下领域具有广泛的应用
再生医学、疾病建模和药物筛选。在细胞重编程过程中,细胞经历
表观遗传变化导致细胞表型转换。然而,生物物理因素是否以及如何
通过表观遗传修饰调节细胞重编程尚不清楚。我们发现
生物物理因素,特别是细胞外基质 (ECM) 硬度,对表观遗传具有深远影响
状态以及将成纤维细胞转化为诱导神经元 (iN) 细胞,效率最高
中等 ECM 硬度,由粘着斑和细胞骨架调节。此外,我们
发现肌动蛋白组装和转运到细胞核中在表观遗传中起着重要作用
调制。根据我们的初步数据,我们假设 (1) 生物物理线索,例如 ECM
硬度调节 FA、肌动蛋白组装/分解、肌动蛋白核运输,从而调节 HAT 活性
调节表观遗传状态和细胞重编程过程,(2) 中等硬度
最适合表观遗传重塑和细胞重编程。为了检验我们的假设,我们提出了三个
具体目标:(1) 研究基质硬度如何通过 FA 和肌动蛋白调节 iN 重编程
细胞骨架,(2) 阐明基质刚度如何调节 HAT 和表观遗传状态以开启神经元
iN 重编程期间的基因,以及(3)确定肌动蛋白核运输在基质刚度中的作用-
iN 重编程过程中 HAT 和表观遗传状态的调节。我们汇集了多学科
团队拥有机械生物学、细胞工程、高通量基因组和表观基因组方面的专业知识
分析和活细胞成像一起工作并研究潜在的生物物理和生物学
机制。我们提出的研究将是第一个阐明 ECM 刚度如何调节的研究之一
细胞重编程的转录组和表观遗传变化,以及 ECM 硬度如何调节局部
细胞重编程的粘附和细胞骨架。该项目的研究结果将揭示新的
细胞命运决定机制,将在细胞和组织工程中具有广泛的应用,
疾病建模和药物发现,为疾病的优化和开发提供合理依据
用于体细胞重编程的新型生物材料。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Song Li其他文献
Song Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Song Li', 18)}}的其他基金
Nanoparticles-mediated combination therapy for breast cancer
纳米颗粒介导的乳腺癌联合疗法
- 批准号:
10617544 - 财政年份:2023
- 资助金额:
$ 32.48万 - 项目类别:
Multimodal wireless electrical stimulation for tissue regeneration
用于组织再生的多模式无线电刺激
- 批准号:
10615764 - 财政年份:2022
- 资助金额:
$ 32.48万 - 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
- 批准号:
10703786 - 财政年份:2022
- 资助金额:
$ 32.48万 - 项目类别:
Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
- 批准号:
10491279 - 财政年份:2021
- 资助金额:
$ 32.48万 - 项目类别:
Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
- 批准号:
10687264 - 财政年份:2021
- 资助金额:
$ 32.48万 - 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
- 批准号:
10442707 - 财政年份:2019
- 资助金额:
$ 32.48万 - 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
- 批准号:
10202507 - 财政年份:2019
- 资助金额:
$ 32.48万 - 项目类别:
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy
用于术后癌症免疫治疗的血小板介导的检查点抑制剂递送
- 批准号:
10668316 - 财政年份:2019
- 资助金额:
$ 32.48万 - 项目类别:
相似海外基金
Photoresponsive, biocompatible materials for reconfigurable intraocular lenses
用于可重构人工晶状体的光响应、生物相容性材料
- 批准号:
DH-2022-00249 - 财政年份:2022
- 资助金额:
$ 32.48万 - 项目类别:
Discovery Horizons
Telemetric mouthguard sensor system with biocompatible materials and MEMS techniques for unconstrained human assessment
采用生物相容性材料和 MEMS 技术的遥测护牙套传感器系统,可实现不受约束的人体评估
- 批准号:
19KK0259 - 财政年份:2019
- 资助金额:
$ 32.48万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (B))
Development of Ion-sensing Membranes Modified Chemically with Biocompatible Materials for Analysis of Biological Samples
开发用于生物样品分析的生物相容性材料化学修饰的离子传感膜
- 批准号:
18K05172 - 财政年份:2018
- 资助金额:
$ 32.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The use of 3D printing techniques in the preparation of biocompatible materials
3D打印技术在生物相容性材料制备中的应用
- 批准号:
1942009 - 财政年份:2017
- 资助金额:
$ 32.48万 - 项目类别:
Studentship
Human periodontal ligament cell adhesions on biocompatible materials
人牙周膜细胞在生物相容性材料上的粘附
- 批准号:
26670892 - 财政年份:2014
- 资助金额:
$ 32.48万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Construction and usage of a mouse or human synthetic lymphoid tissue using biocompatible materials.
使用生物相容性材料构建和使用小鼠或人类合成淋巴组织。
- 批准号:
16590408 - 财政年份:2004
- 资助金额:
$ 32.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DESIGN AND IMPLEMENTATION OF NEW BIOCOMPATIBLE MATERIALS
新型生物相容性材料的设计与实现
- 批准号:
6178836 - 财政年份:2000
- 资助金额:
$ 32.48万 - 项目类别:
DESIGN AND IMPLEMENTATION OF NEW BIOCOMPATIBLE MATERIALS
新型生物相容性材料的设计与实现
- 批准号:
2708568 - 财政年份:1999
- 资助金额:
$ 32.48万 - 项目类别:
DESIGN AND IMPLEMENTATION OF NEW BIOCOMPATIBLE MATERIALS
新型生物相容性材料的设计与实现
- 批准号:
6018399 - 财政年份:1999
- 资助金额:
$ 32.48万 - 项目类别:
Synthesis of Biocompatible Materials Having Blood-Group Antigenic 01 igosaccharide Chain
具有血型抗原01寡糖链的生物相容性材料的合成
- 批准号:
02650662 - 财政年份:1990
- 资助金额:
$ 32.48万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)














{{item.name}}会员




